Up a level |
Wiviott, S.D. and Raz, I. and Bonaca, M.P. and Mosenzon, O. and Kato, E.T. and Cahn, A. and Silverman, M.G. and Zelniker, T.A. and Kuder, J.F. and Murphy, S.A. and Bhatt, D.L. and Leiter, L.A. and McGuire, D.K. and Wilding, J.P.H. and Ruff, C.T. and Gause‑Nilsson, I.A.M. and Fredriksson, M. and Johansson, P.A. and Langkilde, A.-M. and Sabatine, M.S. and for the DECLARE–TIMI 58 Investigators* and Ukraine: and Karpenko, O. and Tkach, S. and Vlasenko, M. and Fushtey, I. and Pertseva, T. and Reshotko, D. and Mostovoy, Y. and Vizir, V. and Kraiz, I. and Amosova, K. and Batushkin, V. and Tseluyko, V. and Koval, O. (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine = N Engl J Med, 380 (4). pp. 347-357. ISSN 0028-4793 (print); 1533-4406 (online)